Today we reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with our business performance well on track to deliver our Full-Year Outlook. Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. We welcomed Jean-Marc Huët as our new Chairman of the Board in May, and welcomed Wolfgang Wienand as our new CEO in July. We also continued to make progress on our ESG commitments. Our emissions targets were validated by the Science Based Targets initiative (SBTi) in the First Half, and we signed a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026. Read more about our progress in H1 2024 here: https://lnkd.in/diMHZF9m #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults
Keep growing!
Impressive growth! Looking forward to a better second half.
Congratulations to all the talented personnel at Lonza who made this possible!
congratulations to this impressive growth :).
Moving forward!
Amazing strides
Impressive growth!
Well done!
Inspiring!
Associate Director, EHS Lead Construction Safety, Global Engineering at LONZA
1moCongrats, moving forward 👍